Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Atterocor Begins ACC Trial | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Atterocor Begins ACC Trial

Orphan treatment to enroll 21 patients

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Atterocor, Inc. has initiated a Phase I trial of ATR-101 for the treatment of adrenocortical carcinoma (ACC). ATR-101 is a novel, oral drug candidate that has shown selective effects on cells derived from the adrenal cortex in a variety of preclinical studies.

Atterocor’s first-in-human study is designed to establish the safety and tolerability of ATR-101 in patients with advanced ACC, whose disease has progressed on standard therapy. Tumor and biomarker responses will also be observed. The Phase I trial is being conducted at the University of Michigan Comprehensive Cancer Center in Ann Arbor and The University of Texas MD Anderson Cancer Center in Houston, and expects to enroll 21 patients.

ATR-101 has received Orphan Drug Designation from both the FDA and EMA. ACC is often fatal and affects approximately 1,000 patients in the U.S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics